They just injected youth genes into a human eye. On June 9, 2026, a patient with glaucoma became the first human ever dosed with ER-100 — an epigenetic reprogramming gene therapy designed not just to slow aging, but to reverse it. In this solo explainer, Dr. Robert Lufkin breaks down the science of partial cellular reprogramming, the Harvard study that restored vision in old mice, the built-in genetic safety switch, and what this first-in-human trial really means — and doesn't mean — for the ...